查看購物車
  • Simplified Chinese
  • Japanese
  • Korean
癌症診斷市場：全球 2024-2029
市場調查報告書
商品編碼
1592137

癌症診斷市場：全球 2024-2029

The World Market for Cancer Diagnostics, 2024-2029
出版日期: | 出版商: Kalorama Information | 英文 295 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

癌症診斷領域正在不斷發展，分子和蛋白質生物標記對於準確診斷、治療選擇、治療效果監測和癌症復發的早期發現至關重要。

本報告探討了全球癌症診斷市場，重點關注關鍵類別，同時涵蓋影像、血液學、臨床化學、流式細胞儀、巴氏抹片和傳統染色。它分析了影響腫瘤 IVD 市場的關鍵發展、產品發佈和監管公告，並提供了 2024 年至 2029 年市場成長的預測。

目錄

第 1 章執行摘要

第 2 章簡介、背景與概述

  • 全球癌症負擔
  • 癌症概述
  • 癌細胞的生物化學
  • 癌症生長的原因可能為治療提供線索
  • 環境因子、DNA、RNA
  • 細胞癌基因
  • 腫瘤抑制基因
  • IVD 應用範圍廣泛
  • 組織學與細胞學 原位雜交（ISH）
  • 免疫測定
  • 聚合酶鍊式反應 (PCR)
  • 伴隨診斷
  • 藥物基因匹配的預測性生物標記測試
  • DNA 和 RNA 變異體
  • 遺傳性癌症的診斷
  • 廣泛使用的癌症標記物
  • 癌症治療方法
  • 什麼是精準癌症治療？

第3章 市場趨勢

  • 精準醫療、伴隨診斷及相關應用的成長
  • 藥物診斷檢測
  • 基於液體活檢的非侵入性癌症分子診斷
  • 循環腫瘤細胞 (CTC) 檢測
  • 樣品收集產品 外泌體定序
  • 次世代定序檢測
  • 全基因組序列分析
  • 外顯子定序 RNA定序
  • 法規的影響
  • 公司
  • 進階分析解決方案
  • 自動化組織學
  • 人工智慧
  • 質譜法
  • 監理與報銷趨勢
  • 保險報銷方面的進步與課題 下一代定序覆蓋範圍 伴隨診斷的監理發展
  • 實驗室測試 (LDT)
  • 食品藥物管理局
  • 98/79/EC 指令
  • 加拿大衛生部的變化與預期行動
  • 國際成長機會

第4章 市場收益及預測

第5章 競爭分析

第6章 公司簡介

  • Abbott Diagnostics
  • Agendia BV
  • Agilent Technologies
  • Asuragen (Bio-Techne)
  • Beckman Coulter (Danaher)
  • Becton, Dickinson and Company (BD)
  • Bio-Rad Laboratories
  • Biocartis
  • Biodesix
  • Biotheranostics, Inc. (Hologic)
  • Danaher Corp.
  • Exact Sciences
  • Exosome Diagnostics (Bio-Techne)
  • Hologic
  • Illumina
  • Leica Biosystems (Danaher)
  • Menarini-Silicon Biosystems
  • Qiagen
  • Roche
  • Sysmex Inostics
  • Thermo Fisher Scientific
簡介目錄
Product Code: 24-037

The landscape of cancer diagnostics is evolving with molecular and protein biomarkers indispensable for accurate diagnosis, therapy selection, monitoring treatment response, and early detection of cancer recurrence. Kalorama Information's "The World Market for Cancer Diagnostics, 2024-2029" delivers an authoritative and comprehensive analysis of the global cancer in vitro diagnostics (IVD) market, including industry-defining trends, market sizing, and growth opportunities.

This report offers an in-depth review of the cancer IVD market, including expert insights into significant segment markets:

  • Oncology molecular assays (including companion diagnostics)
  • Molecular screening for colorectal cancer
  • Immunohistochemistry (IHC)
  • Tumor marker immunoassays
  • In situ hybridization (ISH/FISH)
  • Human papillomavirus (HPV) tests
  • Circulating tumor cell (CTC) assays

While focusing on these pivotal categories, the report provides limited coverage of imaging, hematology, clinical chemistry, flow cytometry, Pap smears, and traditional stains. Key developments, product launches, and regulatory announcements that shape the cancer IVD market are analyzed, along with forecasts for market growth from 2024 to 2029.

Key Highlights

  • Shift to Biofluid-Based Diagnostics: Although tissue-based diagnostics dominate the current market, there is growing momentum toward biofluid-based tests (e.g., blood, urine) for cancer detection and monitoring.
  • Market Dynamics: The forecasted growth reflects anticipated product innovations, cancer epidemiology trends, and demographic shifts, with revenue estimates based on factory-level sales to end users.
  • Comprehensive Insights: The report incorporates global cancer statistics, technological advancements, and competitive trends to provide a nuanced view of the market's evolution.

Report Structure

  • 1. Executive Summary - A concise overview of key findings and market scope.
  • 2. Introduction and Overview - Background and terminology for context.
  • 3. Market Trends - Emerging trends shaping the cancer diagnostics industry.
  • 4. Market Revenues and Forecasts - Detailed revenue projections by segment through 2029.
  • 5. Competitive Analysis - Analysis of key market players and competitive developments.
  • 6. Corporate Profiles - Profiles of leading companies in the cancer diagnostics space.

Table of Contents

Chapter 1: Executive Summary

  • Overview
  • Scope and Methodology
  • Market Overview and Analysis
    • Figure 1-1: Global Cancer IVD Market Size and Forecast, 2024-2029 ($ million)

Chapter 2: Introduction, Background, and Overview

  • Global Cancer Burden
    • Figure 2-1: Incidence of Cancer, by Type, 2020 (Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Oesophagus, Prostate, Stomach, Thyroid)
    • Figure 2-2: Global Distribution of Cancer Incidence, Estimated Number of New Cases, by Type, 2020 (%) (Breast, Cervix Uteri, Colorectum, Liver, Lung, Prostate, Stomach, Thyroid, Other Cancers)
  • Introduction to Cancer
  • Biochemistry of Cancer Cells
  • Causes of Cancer Growth May Shed Light on Treatment
  • Environmental Factors, DNA, RNA
    • Table 2-1: Virus Association with Human Cancer
  • Cellular Oncogenes
  • Tumor Suppressor Genes
  • Large Range of IVDs Applied
  • Histology and Cytology
  • In Situ Hybridization (ISH)
  • Immunoassays
  • Polymerase Chain Reaction (PCR)
  • Companion Diagnostics
    • Table 2-2: FDA Approved or Cleared Companion Diagnostic (CDx) Tests and Corresponding Therapies, Oncology
    • Table 2-3: Selected Major Biomarkers in Oncology Personalized Medicine Tests
  • Predictive Biomarker Tests for Drug-Gene Match
  • DNA and RNA Variants
    • Table 2-4: Human Genome and Cancer Gene Identification
    • Table 2-5: Relevant DNA/RNA Variants for Top Six Cancer Types (Breast, Colon, Gastric, Liver/Biliary, Lung, Prostate)
    • Table 2-6: Relevant DNA/RNA Variants for Top Six Cancer Types (excl. top six) (Brain, Cervical, Esophagus, Leukemia, Lymphoma, Melanoma, Ovarian, Pancreatic, Sarcoma, Thyroid)
  • Diagnostics in Hereditary Cancer Diagnosis
    • Table 2-7: Select Innovations in Molecular Cancer Risk Detection and Prevention
    • Table 2-8: Selected Companies Offering LDTs for Hereditary Risk of Cancer
  • Cancer Markers in Widespread Usage
  • Cancer Treatment Approaches
    • Table 2-9: Characteristics of Cancer Treatment Approaches (Chemotherapy, Hormone Therapy, Precision Therapy)
  • What is Precision Cancer Therapy?
    • Table 2-10: Industry Recognized Terms for Companion Diagnostics and Personalized Medicine

Chapter 3: Market Trends

  • Growth in Precision Medicine, Companion Diagnostics, Related Applications
    • Table 3-1: Selected Molecular Companion and Complementary Assays for Cancer
    • Table 3-2: Selected Pharmacogenomic Biomarkers and Drugs' Labeling, FDA
    • Table 3-3: Selected FDA Cleared/Approved Companion Diagnostic Tests and Therapeutic Application
  • Pharmacodiagnostic Tests
    • Table 3-4: Selected Liquid Biopsy Innovations
  • Liquid Biopsy-based Non-Invasive Cancer Molecular Diagnostics
  • Circulating Tumor Cell (CTC) Tests
  • Sample Collection Products
  • Exosome Sequencing
  • Next-Generation Sequencing Tests
  • Whole-Genome Sequencing
  • Exome Sequencing
  • RNA Sequencing
  • Regulatory Influences
  • Companies
  • Advanced Analysis Solutions
    • Table 3-5: Selected Advanced Histology Techniques
  • Automation of Histology
    • Table 3-6: Selected Histology Lab Automation Technologies
    • Table 3-7: Histology Information Technology Tools
  • Artificial Intelligence
  • Mass Spectrometry
    • Table 3-8: Selected Mass Spectrometry-Based Oncology Tests
  • Regulatory and Reimbursement Trends
  • Reimbursement Breakthroughs and Challenges
  • Next Generation Sequencing Coverage
  • Companion Diagnostics Seeing Development in Regulations
    • Table 3-9: FDA Approved Companion Diagnostics Labeled for Identifying Patients with NSCLC whose Tumors have EGFR Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations and the Associated Therapeutic Products
    • Figure 3-1: Growth in Precision Cancer Therapeutics by Company 2010 vs. 2022 ($ million)
    • Figure 3-2: Growth Trend by Company, 2010-2022 CAGR: Precision Cancer Therapeutics (%)
  • Laboratory Developed Tests (LDTs)
  • Food and Drug Administration
  • Directive 98/79/EC
  • Health Canada Changes and Forecasted Action
  • International Growth Opportunities

Chapter 4: Market Revenues and Forecast

  • Market Revenue 2024-2029
    • Table 4-1: Cancer IVD Market Revenues, by Segment, 2024-2029 ($ million) (Colon Cancer Molecular Screen; CTCs; HPV; Immunoassay - IHC; Immunoassay - Tumor Markers; ISH/ FISH; Oncology Molecular Assays [including. CDx])
    • Figure 4-1: Cancer IVD Market Revenues, by Segment, 2024-2029 ($ million) (Colon Cancer Molecular Screen; CTCs; HPV; Immunoassay - IHC; Immunoassay - Tumor Markers; ISH/ FISH; Oncology Molecular Assays [including. CDx])
    • Figure 4-2: Cancer IVD Market Revenue, CAGR by Segment, 2024-2029 (%) (Colon Cancer Molecular Screen; CTCs; HPV; Immunoassay - IHC; Immunoassay - Tumor Markers; ISH/ FISH; Oncology Molecular Assays [including. CDx])
    • Table 4-2: Cancer IVD Market Revenues, Share by Segment, 2024 vs. 2029 (%) (Colon Cancer Molecular Screen; CTCs; HPV; Immunoassay - IHC; Immunoassay - Tumor Markers; ISH/ FISH; Oncology Molecular Assays [including. CDx])
    • Figure 4-3: Cancer IVD Market Revenues, Share by Segment, 2024 (%) (Colon Cancer Molecular Screen; CTCs; HPV; Immunoassay - IHC; Immunoassay - Tumor Markers; ISH/ FISH; Oncology Molecular Assays [including. CDx])
  • Molecular Cancer Test Regional Distribution
    • Table 4-3: Global Molecular Cancer Test Sales Distribution, by Region, 2024 (%) (Asia Pacific, Europe, North America, Rest of World)
    • Figure 4-4: Global Molecular Cancer Test Sales Distribution, by Region, 2024 (%) (Asia Pacific, Europe, North America, Rest of World)
  • Histology and Cytology
    • Table 4-4: Global Histology/Cytology Sales Distribution, by Region, 2024 (%) (Asia Pacific, Europe, North America, Rest of World)
    • Figure 4-5: Global Histology/Cytology Sales Distribution, by Region, 2024 (%) (Asia Pacific, Europe, North America, Rest of World)
  • Molecular Cancer Diagnostics Segment by Technology/Method
    • Table 4-5: Techniques Used in Molecular Cancer Diagnostics, 2024 & 2029 (%) (Arrays, ISH, NGS, PCR, Others)
    • Figure 4-6: Techniques Used in Molecular Cancer Diagnostics, 2024 & 2029 (%) (Arrays, ISH, NGS, PCR, Others)
  • HPV Market and Regional Distribution
    • Table 4-6: Selected HPV Test Innovations
    • Table 4-7: Global HPV Test Sales Distribution, by Region, 2024 (%) (Asia Pacific, Europe, North America, Rest of World)
    • Figure 4-7: Global HPV Test Sales Distribution, by Region, 2024 (%) (Asia Pacific, Europe, North America, Rest of World)
  • Drivers and Challenges
  • Clinical Utility of Molecular Diagnostics
  • Technological Advancements Including NGS Adopted Incrementally

Chapter 5: Competitive Analysis

  • Recent Regulatory Approvals
    • Table 5-1: Recent Regulatory Approvals in Cancer IVD, May 2022 - December 2024
  • Immunoassay Competitive Trends
  • IHC Market
  • Competition in ISH
  • Molecular Cancer Diagnostics Landscape
  • HPV
  • Liquid Biopsy and CTCs
  • Deals and Collaborations
    • Table 5-2: Recent Deals and Collaborations in Cancer IVD, January 2022 - December 2024
    • Table 5-3: CDx Relevant Partnerships and Collaborations
    • Table 5-4: Product/ Technology Introductions in Cancer IVD, January 2022 - November 2024

Chapter 6: Corporate Profiles

  • Abbott Diagnostics
    • Company Overview
      • Companion Testing
      • Liquid Biopsy
  • Agendia BV
    • Company Overview
  • Agilent Technologies
    • Company Overview
      • Agilent in Genomics
      • Cytogenetic Analysis
      • Sequencing
      • CRISPR
      • Flow Cytometry
      • Companion Diagnostics
  • Asuragen (Bio-Techne)
    • Company Overview
  • Beckman Coulter (Danaher)
    • Company Overview
      • Immunoassays
  • Becton, Dickinson and Company (BD)
    • Company Overview
      • Cytology and HPV
      • Flow Cytometry
      • Licensing
  • Bio-Rad Laboratories
    • Company Overview
      • Immunoassays
      • Liquid Biopsy
      • Droplet Digital PCR
  • Biocartis
    • Company Overview
  • Biodesix
    • Company Overview
  • Biotheranostics, Inc. (Hologic)
    • Company Overview
  • Danaher Corp.
    • Company Overview
      • Other Acquisitions
  • Exact Sciences
    • Company Overview
  • Exosome Diagnostics (Bio-Techne)
    • Company Overview
  • Hologic
    • Company Overview
  • Illumina
    • Company Overview
  • Leica Biosystems (Danaher)
    • Company Overview
      • Digital Pathology
      • Stain Reagents
      • Lab Systems
      • Sample Handling
      • Circulating Tumor Cells (CTCs)
      • Artificial Intelligence
  • Menarini-Silicon Biosystems
    • Company Overview
  • Qiagen
    • Company Overview
      • Precision Medicine / Companion Diagnostics
      • Sample Prep, Informatics
      • Digital PCR
      • Bioinformatics
      • Liquid Biopsy
  • Roche
    • Company Overview
      • HPV
      • Cancer Companion Testing
      • Liquid Biopsy
      • IT in Anatomical Pathology
      • Information Technology
      • Roche Tissue Diagnostics / Ventana
      • Immunohistochemistry - IHC
      • Cervical Cancer Screening
      • Companion Diagnostics
  • Sysmex Inostics
    • Company Overview
      • Hematology
      • Coagulation
      • Urinalysis
      • Immunoassays
      • Lab Information System
      • Information Technology
      • Flow Cytometry
      • Precision Medicine / Companion Test Diagnostics
      • Liquid Biopsy
      • Exosomes
      • Oncology
  • Thermo Fisher Scientific
    • Company Overview
      • Next Generation Sequencing
      • Liquid Biopsy
      • Oncology Companion Diagnostics